Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.
about
A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.Increase of plasma transforming growth factor beta (TGF beta) during immunotherapy with IL-2.Cutaneous response to recombinant interleukin 2 in human immunodeficiency virus 1-seropositive individuals.Circulating cytokines as mediators of fever.Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisoloneEvidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapySelective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.Pathogenesis of malaria and clinically similar conditions.Effects of nitric oxide (NO) synthesis inhibition on antitumor responses during interleukin-2 (IL-2) treatment of mice.Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.Interleukin 2-induced increase of vascular permeability without decrease of the intravascular albumin pool.Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response.Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.HLA associations in the antitumor response against malignant melanoma.Invited commentary on David Fedson's articleRetrospective analysis of peripheral blood stem cell transplantation for the treatment of high-risk neuroblastomaRational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice.Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury.Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.Immunotherapy of advanced renal cell carcinoma: Current and future therapies.Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients.Clinical chorioamnionitis at term V: umbilical cord plasma cytokine profile in the context of a systemic maternal inflammatory response.Clinical chorioamnionitis at term IV: the maternal plasma cytokine profile.Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma.Acute phase responses induced in dwarf goats by r.BolL(-1beta), r.BolL(-2) and r.BolFN(-gamma).Interleukin 2 induces tumor necrosis factor gene expression in vivo.Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment.Adverse Events in Cancer Immunotherapy.A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma.Biofluid Proteomics and Biomarkers in Traumatic Brain Injury.
P2860
Q28260123-24B78721-E25B-41A1-8ECC-65169475989EQ33370145-D10E93C0-E6EA-4834-B5C1-D591A89F1951Q33488580-F816DD0D-3F18-4931-B79A-71A768008804Q33717893-0692EA78-70AB-4691-A671-120E24DB0022Q34102600-F81EDE3A-099C-47AF-98B5-65A7EB7B6538Q34625248-6771F70F-688C-4B89-92F8-7AD8E6E58E18Q34799677-E6615B05-F63E-4FC0-B8F4-18ED8FC6FC14Q35599161-3A01BA85-D5D4-4AB0-9CC5-9291C20D5C44Q35823805-AC148240-4F85-4819-A1DB-551DD5114041Q35838590-3736EBA4-F4E6-40F3-921B-14E376B3DFD9Q35938791-DA74EABF-16EF-4585-B576-F1B04D1A68D7Q35977092-0A834112-B14F-4EF8-9482-215764D4406BQ35992936-64FE5697-A04A-4361-81A9-7C4C736C448FQ36079858-13BF6122-9718-4CE9-A9F9-20BCC2FCCD53Q36120970-A04C9401-2AE3-4A0F-AD49-DB6C191F55A9Q36356738-A2E70504-5448-45D9-BBDA-1C5B5D05FA86Q36924466-6CC79571-9D3D-4E8A-968D-D8179C9DA059Q37086826-DB33CE1B-6903-48F0-9EEB-B57C17D74C42Q37222520-6DABF0E4-6FD0-4692-818B-147586651893Q37340647-F1031CBE-81E4-4258-92FA-CF20685F7F7CQ37354383-9D42944B-1353-4E0E-96F6-3A0A3085B8E9Q37374156-8E97799C-4244-4778-BBC1-967623827765Q37385098-636DF1F5-7F85-42B8-875B-05F67DF88BA8Q37686896-A211DA7B-7B52-4A16-854E-0E0FE6923A43Q38834167-890AA39B-4778-45BB-AB52-5E868905A5A9Q39714477-5F243CA3-1342-4D61-B160-EC7676ECF44FQ40139863-9BC4803F-83AA-4B53-B24D-FD0B4E209961Q40140125-5A982060-ABE3-459D-BC9D-6539FF9D27D8Q40180453-542578B8-9E4F-41E1-8FD7-F9B76DE3B41CQ40738430-84254A28-1D5A-4B81-9E80-731406195E78Q41169638-9CB5F2BF-9089-4A55-83E0-A78DB1D5D3DCQ41661156-9C9C2306-5653-439A-AECF-FFC743CBE308Q45376634-3D93B8DA-4CF9-4C3D-9EC6-A293BE5700F6Q46884498-4299C3CC-7C58-4349-99AB-522BA39883E5Q50545431-DA08C77C-5139-477D-BB36-FC1941492F83Q50642014-50D5A4A0-7283-42F9-92DB-C71B327BC935
P2860
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Induction of circulating tumor ...... n-2 (IL-2) in cancer patients.
@en
type
label
Induction of circulating tumor ...... n-2 (IL-2) in cancer patients.
@en
prefLabel
Induction of circulating tumor ...... n-2 (IL-2) in cancer patients.
@en
P2093
P921
P356
P1476
Induction of circulating tumor ...... n-2 (IL-2) in cancer patients.
@en
P2093
C A Dinarello
D R Parkinson
H A Bernheim
J G Cannon
J W van der Meer
M B Atkins
R P Numerof
P2888
P304
P356
10.1007/BF00916947
P50
P577
1988-11-01T00:00:00Z
P5875
P6179
1019136705